Loading stock data…
JNJ
$229.85+2.50 (+1.10%)
Pre-Market$230.04+0.19 (+0.08%)· Last close Apr 30
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $229.85. The stock is currently 9% below its 52-week high of $251.71, remaining 12.4% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why JNJ maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
UNHPFEABBV
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$229.85
Potential Upside
14.9%
Whystock Fair Value$264.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Buy
Mean target$252.42+9.8%
Range$155.00 – $285.00
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$544.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Strong income play. Yield provides a meaningful total return floor.
237.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.79%
Volume
Today's trading volume
8.14M
Recent News
Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry
Organon & Co. (NYSE:OGN) was among the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in AI-related stocks. Mentioning that they own NVO shares, a caller inquired if they should sell them and start a position in OGN, and in response, Cramer said: No, Organon’s done. Organon’s been, got a […]
AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says
AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competit
Half of Americans Think $1,000 Is Needed to Start Investing, They’re Wrong
A perception gap is keeping millions of Americans on the sidelines of the stock market. This is especially true if you look at Charles Schwab’s 2025 Modern Wealth Survey, which found that roughly half of non-investors say they do not have enough money to invest, even as brokerage minimums have collapsed and fractional shares let ... Half of Americans Think $1,000 Is Needed to Start Investing, They’re Wrong
3 Unstoppable Growth Stocks For Years Of Passive Income
Passive income separates a paycheck from a portfolio. Earned income stops when you stop working, but dividends landing quarterly do not. With layoffs rippling through tech and consumer staples in 2026 and housing and grocery costs rising, more investors seek cash flow regardless of macro headlines. High-yield names get attention, but durable passive income comes ... 3 Unstoppable Growth Stocks For Years Of Passive Income
Johnson & Johnson (JNJ) Highlights Sustained Efficacy in Vivacity-MG3 Trial
We recently compiled a list of the 10 Most Popular Stocks on Robinhood in 2026. Johnson & Johnson is one of the most popular stocks on Robinhood. TheFly reported on April 22 that JNJ released updated findings from its Phase 3 Vivacity-MG3 trial and ongoing extension study evaluating IMAAVY (nipocalimab-aahu) in adults with generalized myasthenia […]